Anti-Coagulants - Greece

Greece

In Greece, the revenue in the Anti-Coagulants market is predicted to reach US$42.01m by the year 2024.
This market is expected to demonstrate an annual growth rate (CAGR 2024-2029) of 6.76%, leading to a market volume of US$58.26m by 2029.
When compared globally, United States is projected to generate the highest revenue in this industry, amounting to US$16,740.00m in 2024.
Greece's market for anti-coagulants is witnessing a surge in demand due to an aging population and an increase in cardiovascular diseases.

Key regions: Australia, Japan, United States, Germany, Europe

Market

Region

Region comparison

Currency

Analyst Opinion

The Anti-Coagulants market in Greece has been showing interesting trends over the past few years.

Customer preferences: Patients in Greece have been increasingly opting for newer oral anti-coagulants over traditional options such as warfarin. This can be attributed to the convenience of not requiring regular blood tests and dosage adjustments. Additionally, there is a growing preference for drugs with a lower risk of bleeding complications.

Trends in the market: The Anti-Coagulants market in Greece has been growing at a steady pace due to the increasing prevalence of cardiovascular diseases and the aging population. The market has witnessed a shift towards the use of direct oral anti-coagulants (DOACs), which have been gaining popularity due to their ease of use and better safety profile. The market is also witnessing an increase in the number of patients being treated with anti-coagulants for non-valvular atrial fibrillation.

Local special circumstances: Greece has been facing economic challenges in recent years, which has led to a reduction in healthcare spending. This has resulted in a shift towards the use of generic drugs in the country. The Greek government has also implemented measures to reduce the prices of pharmaceuticals, which has resulted in a decrease in the prices of anti-coagulants.

Underlying macroeconomic factors: The prevalence of cardiovascular diseases in Greece has been increasing due to factors such as an aging population, unhealthy dietary habits, and sedentary lifestyles. The Greek healthcare system has been under pressure due to the economic crisis in the country, which has resulted in a reduction in healthcare spending. However, the government has been taking steps to improve the healthcare system, which is expected to have a positive impact on the Anti-Coagulants market in the country.

Methodology

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.